Censo Biotechnologies check-in to Roslin's Research Hotel
Censo Biotechnologies Ltd. (“Censo”), a leader in the creation of induced Pluripotent Stem Cells (iPSCs), is pleased to be one of the first guests to take up accommodation at Roslin Innovation Centre’s novel Research Hotel.
Censo works on a bespoke basis with companies to provide a range of cell products and screening services for their specific needs in neurodegenerative and rare diseases - providing access to existing human iPSC lines and ethically sourced specific human tissue clinically to create relevant iPSC lines from large cohorts of individuals. Censo can also use these clinically relevant iPSC lines to generate patient-derived neuronal and microglia cells which we use to offer standard and bespoke assay services, in areas such as Alzheimer’s, Parkinson’s, ataxias and ALS.
The company had been based at Roslin BioCentre since early 2016, home to numerous successful life science companies. After 20 years this science park has now been vacated with many tenant companies relocating to Roslin Innovation Centre or elsewhere within the Midlothian Science Zone.
Roslin Innovation Centre is part of an exciting new £30 million multi-purpose business gateway within the Charnock Bradley Building, located at the epicentre of the renowned Easter Bush Campus. Accommodating a new Research Hotel, this provides established companies and start-ups with ready to use state-of-the art office and lab space with access to standard lab equipment. This is an ideal interim solution for Censo as it prepares for its next stage of growth, and during construction of bespoke office and lab space at the nearby Pentlands Science Park.
Kevin Bruce, COO of Censo Biotechnologies said: “The Research Hotel provides our team of 25 with ready to use state-of-the-art office and lab space with access to standard lab equipment and tissue culture rooms off the main lab. This is an ideal stepping stone for us whilst we develop our custom facilities for the long-term at Pentlands Science Park, which will complement our existing drug discovery facilities at the Babraham Institute, in Cambridge.”
Simon MacKenzie, CBO of Censo Biotechnologies adds: “Being located within a collaborative environment, offers a variety of business and innovation opportunities, enabling connections and collaborations with other resident companies.”